Research programme: macrophage-1-antigen modulators - Sujana Biotech

Drug Profile

Research programme: macrophage-1-antigen modulators - Sujana Biotech

Alternative Names: Mac-1:GPIb alpha inhibitors - Sujana Biotech; Macrophage-1-antigen modulators - Sujana Biotech

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sujana Biotech
  • Class Anti-inflammatories; Monoclonal antibodies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Macrophage 1 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammation; Vascular disorders

Most Recent Events

  • 01 Nov 2017 Macrophage-1-antigen modulators - Sujana Biotech is available for licensing as of 01 Nov 2017. http://www.sujanabio.com/partners/
  • 22 Sep 2017 Preclinical trials in Inflammation in USA (Parenteral) (Sujana Biotech pipeline)
  • 22 Sep 2017 Preclinical trials in Vascular diseases in USA (Parenteral) (Sujana Biotech pipeline)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top